| S. No. |
Antimicrobial |
Control |
Treated |
| G-I |
G-II |
G-III |
| Day-5 |
Day-10 |
Day-10 |
| 1 |
Amikacin |
>32 |
>32 |
>32 |
>32 |
| 2 |
Amoxicillin/k- clavulanate |
≤8/4 |
≤8/4 |
>16/8 |
≤8/4 |
| 3 |
Ampicillin/sulbactam |
≤8/4 |
16/8 |
>16/8 |
≤8/4 |
| 4 |
Ampicillin |
>16 |
>16 |
>16 |
≤8 |
| 5 |
Aztreonam |
>16 |
>16 |
>16 |
≤8 |
| 6 |
Cefazolin |
16 |
16 |
16 |
16 |
| 7 |
Cefepime |
16 |
16 |
16 |
≤8 |
| 8 |
Cefotaxime |
>32 |
>32 |
32 |
≤16 |
| 9 |
Cefotetan |
>32 |
>32 |
>32 |
>32 |
| 10 |
Cefoxitin |
>16 |
>16 |
>16 |
>16 |
| 11 |
Ceftazidime |
>16 |
>16 |
>16 |
≤8 |
| 12 |
Ceftriaxone |
≤8 |
≤8 |
≤8 |
≤8 |
| 13 |
Cefuroxime |
>16 |
>16 |
>16 |
>16 |
| 14 |
Cephalothin |
16 |
16 |
16 |
16 |
| 15 |
Chloramphenicol |
>16 |
>16 |
>16 |
≤8 |
| 16 |
Ciprofloxacin |
≤1 |
≤1 |
≤1 |
≤1 |
| 17 |
Gatifloxacin |
≤2 |
≤2 |
≤2 |
≤2 |
| 18 |
Gentamicin |
>8 |
>8 |
>8 |
>8 |
| 19 |
Imipenem |
≤4 |
≤4 |
≤4 |
≤4 |
| 20 |
Levofloxacin |
≤2 |
≤2 |
≤2 |
≤2 |
| 21 |
Meropenem |
≤4 |
≤4 |
≤4 |
≤4 |
| 22 |
Moxifloxacin |
≤2 |
≤2 |
≤2 |
≤2 |
| 23 |
Nitrofurantoin |
>64 |
>64 |
>64 |
>64 |
| 24 |
Norfloxacin |
≤4 |
≤4 |
≤4 |
≤4 |
| 25 |
Piperacillin |
≤16 |
≤16 |
≤16 |
≤16 |
| 26 |
Piperacillin/tazobactam |
≤16 |
≤16 |
≤16 |
≤16 |
| 27 |
Tetracycline |
>8 |
>8 |
>8 |
≤4 |
| 28 |
Ticarcillin/k-clavulanate |
≤16 |
≤16 |
≤16 |
≤16 |
| 29 |
Tobramycin |
>8 |
>8 |
>8 |
>8 |
| 30 |
Trimethoprim/sulfamethoxazole |
≤2/38 |
≤2/38 |
≤2/38 |
≤2/38 |
|
| G, stands for group; MIC data is presented in μg/mL |
| Table 2: Effect of biofield treatment on Shigella sonnei to minimum inhibitory
concentration (MIC) of selected antimicrobials. |
